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In the last 20 years, several modalities of neuromodulation, mainly based on non-invasive
brain stimulation (NIBS) techniques, have been tested as a non-pharmacological
therapeutic approach to slow disease progression in amyotrophic lateral sclerosis
(ALS). In both sporadic and familial ALS cases, neurophysiological studies point to
motor cortical hyperexcitability as a possible priming factor in neurodegeneration, likely
related to dysfunction of both excitatory and inhibitory mechanisms. A trans-synaptic
anterograde mechanism of excitotoxicity is thus postulated, causing upper and lower
motor neuron degeneration. Specifically, motor neuron hyperexcitability and hyperactivity
are attributed to intrinsic cell abnormalities related to altered ion homeostasis
and to impaired glutamate and gamma aminobutyric acid gamma-aminobutyric
acid (GABA) signaling. Several neuropathological mechanisms support excitatory
and synaptic dysfunction in ALS; additionally, hyperexcitability seems to drive
DNA-binding protein 43-kDA (TDP-43) pathology, through the upregulation of unusual
isoforms directly contributing to ASL pathophysiology. Corticospinal excitability can
be suppressed or enhanced using NIBS techniques, namely, repetitive transcranial
magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), as
well as invasive brain and spinal stimulation. Experimental evidence supports the
hypothesis that the after-effects of NIBS are mediated by long-term potentiation
(LTP)-/long-term depression (LTD)-like mechanisms of modulation of synaptic activity,
with different biological and physiological mechanisms underlying the effects of tDCS
and rTMS and, possibly, of different rTMS protocols. This potential has led to
several small trials testing different stimulation interventions to antagonize excitotoxicity
in ALS. Overall, these studies suggest a possible efficacy of neuromodulation in
determining a slight reduction of disease progression, related to the type, duration,
and frequency of treatment, but current evidence remains preliminary. Main limitations
are the small number and heterogeneity of recruited patients, the limited “dosage”
of brain stimulation that can be delivered in the hospital setting, the lack of a
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sufficient knowledge on the excitatory and inhibitory mechanisms targeted by specific
stimulation interventions, and the persistent uncertainty on the key pathophysiological
processes leading to motor neuron loss. The present review article provides an update
on the state of the art of neuromodulation in ALS and a critical appraisal of the rationale
for the application/optimization of brain stimulation interventions, in the light of their
interaction with ALS pathophysiological mechanisms.
Keywords: cortical hyperexcitability, repetitive transcranial magnetic stimulation, transcranial direct current
stimulation, neuromodulation, functional status, survival, non-invasive brain stimulation, ALS
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease affecting the cortical, brainstem, and spinal motor
neurons, leading to death due to respiratory failure usually
within 3–5 years of symptom onset. While about 90% of cases
are sporadic, the remaining are familial and usually inherited
as dominant traits. Both familial and sporadic cases have been
associated with mutations of several genes regulating protein
homeostasis, RNA homeostasis, and cytoskeletal dynamics,
with common downstream neuropathological and phenotypical
alterations (1).
Many studies, investigating neurophysiological and
neuropathological alterations in both familial and sporadic
ALS, converge on a “dying-forward” hypothesis at the origin of
the disease, with cortical hyperexcitability as a possible driver
of neurodegeneration. In this context, different molecular
alterations of glutamatergic and gamma aminobutyric acid
(GABA)-ergic neurons and receptors and of astrocytes, as
well as the excitation/inhibition imbalance of motor cortical
circuits, might all contribute the final picture of corticospinal
hyperexcitability. These alterations suggest the possibility of
exploiting therapeutic strategies pointing to hyperexcitability,
targeted to specific molecular and/or functional alterations. Such
a therapeutic approach is further valued by recent evidence that
early cortical hyperexcitability is sufficient to trigger molecular
alterations commonly associated with ALS (2), possibly initiating
upper (UMN) and lower motor neuron (LMN) damage.
Current pharmacological therapeutic attempts point to
excitotoxicity control and neuroprotection. To date, the only
two drugs approved for the treatment of ALS, riluzole, and
edaravone, are targeted to mechanisms of excessive excitability
of corticospinal neurons (CSNs). Both drugs show modest effects
on disease progression (3). Riluzole, available from 1995, acts
by reducing glutamatergic transmission, through pre-synaptic
inhibition of glutamate release or post-synaptic modulation of
ionotropic glutamate receptors, in addition to inactivation of
voltage-gated Na+ channels, and it was shown to determine an
increase of∼3 months in median survival time (4–6). Edaravone,
approved by the Food and Drug Administration in 2017, is
thought to act as a free radical scavenger preventing oxidative
damage and showed a slight slowing in disease progression at
6 months in a selected group of early affected patients without
respiratory failure (7). However, this effect seems to vanish at a
longer follow-up (8).
Starting from 2004, different non-invasive brain stimulation
(NIBS) techniques have been employed to modulate motor
cortical excitability in the attempt to counteract excitotoxicity.
The main attempts have been made with repetitive transcranial
magnetic stimulation (rTMS), allowing repeated activation
of cortical synapses, and with transcranial direct current
stimulation (tDCS), acting on resting membrane potential:
both techniques can produce a prolonged suppression of
neuronal excitability throughmodulation of synaptic plasticity in
physiological conditions (9). Additionally, invasive stimulation
of the motor cortex and of the corticospinal tract by means
of epidural electrodes has been attempted, with the main
purpose of performing a chronic and possibly more effective
stimulation. Since these approaches of brain stimulation exert
their modulatory effects by acting at different levels of
intracortical circuitry, they could be used to target specific
pathogenic mechanisms.
In this review, we provide an update on brain stimulation
interventions applied in ALS and on their potential benefits
and current limitations, in the light of their interaction with
mechanisms of corticospinal excitability.
DYSFUNCTION OF CORTICOSPINAL
CIRCUITS
A full knowledge of ALS pathogenesis is still to be uncovered;
however, the known pathogenic mechanisms and resulting
dysfunctions are fundamental in developing targeted
therapeutic interventions.
The two main histological characteristics of the disease,
described by the terms “amyotrophic” and “lateral sclerosis,”
derive from the degeneration of motor neurons in the anterior
horn of the spinal cord and from axonal loss in the lateral
columns (the lateral corticospinal tract), respectively.
After the initial Charcot’s hypothesis on the primacy of
corticomotoneuronal dysfunction (10), the so-called “dying-
forward” hypothesis, two alternative explanations have been
considered, based on either a dying-back mechanism secondary
to LMN dysfunction (11) or an independent process of upper and
lower motor neuron degeneration (12).
In the last three decades, accumulating evidence
supports the initial hypothesis of the hyperexcitability of
the corticomotoneuronal system as a leading pathogenic
mechanism. This view is supported by several elements: (1)
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prominent muscle wasting in districts with direct corticospinal
projections and sparing of LMN not controlled by corticospinal
tract (i.e., oculomotor and Onuf ’s nuclei motor neurons); (2)
time-dependent spreading of neuropathological alterations
from layer V pyramidal cells to structures under direct
control of corticofugal projections; (3) clinical syndromes
characterized by frontal dysfunction preceding muscle weakness;
(4) neurophysiological evidence of hyperexcitable corticospinal
circuits; (5) cortical hyperexcitability documented before LMN
dysfunction; and (6) evidence of altered glutamatergic signaling
[reviewed in Eisen et al. (13)].
Based on the above considerations, it is assumed that
hyperexcitability represents a common pathogenic mechanism
leading to excitotoxicity and degeneration of upper and lower
motor neurons. Hyperexcitability can be mediated either by
direct pre-synaptic mechanisms (i.e., overstimulation), due to
increased glutamate stimulation, or by indirect post-synaptic
mechanisms (i.e., overreaction), due to altered interneuron
regulation, glutamate receptors, or intrinsic motoneuronal
excitability (14).
The link between UMN hyperexcitability and LMN
degeneration remains a matter of debate, and a mechanism of
glutamate-mediated excitotoxicity from the direct corticospinal
connection is not demonstrated. Indeed, findings on alterations
of spinal circuit excitability in ALS are not conclusive, as
different pathways and interneurons characterize animal models
and humans. We refer the reader to existing literature for details
on the complexity of spinal circuit pathophysiology [e.g., Gunes
et al. (15) for a recent review].
Neurophysiological Insights
The introduction of transcranial magnetic stimulation (TMS)
allowed to activate non-invasively the corticospinal motor
pathways, both directly and trans-synaptically, and then to study
the function of corticospinal projections and intracortical circuits
in physiological and pathological conditions (16). In ALS, specific
TMS protocols allowed to demonstrate an altered excitability
of CSNs and of cortical inhibitory interneurons connected with
CSNs [reviewed in Vucic et al. (17)].
The basic output of TMS of the primary motor cortex (M1),
the motor evoked potential (MEP) recorded from a target
muscle, is the result of activation of the different levels of the
motor pathway, and hence, at central level, it is influenced
by the excitability of upper and lower motor neurons, of
cortical and spinal/brainstem interneurons, as well as by the
motor neuron pool (i.e., the integrity of motor pathway).
Among specific single-pulse TMS parameters of corticospinal
excitability, motor threshold (MT) is defined as the minimum
TMS intensity required to elicit the MEP. Intensity–response
curve of MEP amplitude reflects recruitment of the CSN pool at
increasing stimulation intensities. Additional protocols allow to
study inhibitory intracortical phenomena. The silent period of
electromyographic activity, induced by a single suprathreshold
TMS pulse of the contralateral M1, partly depends on the
activation of cortical GABA-B receptors and can be used
as an index of activation of cortical inhibitory interneurons
(18). Additionally, a paired-pulse TMS protocol, in which a
subthreshold pulse precedes of 1–5ms a suprathreshold test
pulse, produces a “short-interval” intracortical inhibition (SICI)
(19) of the test response, which is believed to be mediated by the
activation of cortical GABA-A receptors (20, 21).
Abnormalities of the above parameters in both sporadic
and familial forms of ALS (i.e., reduced MT, increased
MEP amplitude and recruitment, shorter/absent silent period,
and reduced SICI) point to the occurrence of phenomena
of concomitant increased CSN excitability and of reduced
intracortical inhibitory activity (17). Interestingly, the above
alterations have been observed in the early and pre-symptomatic
stages of sporadic and familial cases of ALS, respectively,
supporting the hypothesis that hyperexcitability can precede
neurodegeneration (22–25). However, it is not clear how TMS
metrics change over time, as conflicting results exist in literature.
The first longitudinal study (26) failed to find a clear change of
TMS parameters over time. Subsequent studies have reported
an initial reduction of MT, followed by a progressive and
eventual cortical inexcitability in later stages (22, 27–29). A recent
prospective study on a large cohort of ALS patients (n = 345),
with a mild–moderate disease severity [mean ALS functional
rating scale (ALSFRS-R): 40.5] at the time of neurophysiological
investigation, reports that cortical hyperexcitability increases
with disease duration, excluding subjects with inexcitable M1
to TMS (30). Of note, in this study, a marked reduction of
excitability or inexcitability to TMS was found in 21% of
ALS patients: the occurrence of inexcitability is expected to
be higher in later stages due to progressive motor neuron
depletion (31, 32).
It remains an open question whether hyperexcitability
represents, at least in part, a compensatory phenomenon of
motor neuron degeneration (33). While increased excitability
following reduced input is a known physiological phenomenon
(34), this hypothesis in ALS is not confirmed by the fact
that ALS mimics (i.e., other neuromuscular disorders, such
as motor neuropathies, spinal muscular atrophy, Kennedy’s
and Hirayama’s diseases, hereditary spastic paraplegia,
neuromyotonia, and myopathies) do not exhibit cortical
hyperexcitability (30). However, it cannot be excluded that
genetically altered motor neurons (35) are more sensitive to the
loss of cortical inhibitory inputs.
Growing body of evidence also reveals that ALS exhibits
subclinical peripheral and central sensory neuron dysfunctions
(36–39). Indeed, somatosensory evoked potential (SEP) studies
have demonstrated an hyperexcitability of somatosensory
cortex, as indicated by enlarged early component of cortical
SEP (i.e., N20, P25), which was more evident in moderate
respect to severe cases of ALS (40) and was associated
to shorter survival (38). In addition, a paired-pulse SEP
study demonstrated a marked reduction of the physiological
inhibition, putting forward an impaired inhibition as a
mechanism underlying cortical hyperexcitability (39) and closely
resembling the TMS data obtained for M1. However, if this
sensory cortical hyperexcitability could reflect a multisystem
neurodegenerative disorder (41) or represent a compensatory
upregulation mechanism related to the functional impairment of
the motor cortex is still debated.
Frontiers in Neurology | www.frontiersin.org 3 February 2021 | Volume 11 | Article 605335
Ranieri et al. Neuromodulation in ALS
Despite the entire picture of pathophysiological mechanisms
of hyperexcitability in ALS remains to be uncovered, the known
physiological alterations support the rationale of interventions
based on reducing corticospinal activity aimed at preventing
upper and/or lower motor neuron excitotoxicity.
Neuropathological Alterations
Although specific mechanisms underlying selective
degeneration of motor neurons in ALS remain unknown,
some neuropathological alterations might underlie degeneration,
abnormal cell excitability, and synaptic transmission and thus
account for cortical circuit dysfunction. Conversely, neuronal
hyperactivity can lead to molecular alterations accounting for
cell dysfunction and degeneration.
Key Aspects of Neuronal Degeneration
Genetic studies have identified a high number of genes associated
with both familial and sporadic ALS; however, both forms show a
substantial convergence in their pathological features leading to
motor neuron degeneration (42).
The neuropathological hallmark of the disease is the
presence of transactivation response DNA-binding protein 43-
kDA (TDP-43) positive inclusions into neuronal cytoplasm
(43, 44) frequently as skein-like inclusions. Small intracellular
eosinophilic inclusions (the so-called Bunina bodies) are also
observed in the spinal cord and brainstem nuclei and are
considered highly specific for the disease (45). Microscopic
examination shows loss of myelinated axons and degeneration
of neurons in the lateral/anterior columns of the spinal
cord, brainstem motor nuclei, and motor cortex, associated
with vacuolization, spongiosis, and reactive astrogliosis (46).
The activation of microglia, which occasionally shows TDP-
43 deposits, further causes the release of proinflammatory
molecules thus supporting inflammation (46). These aspects are
observed in all cases of ALS, which clinical variability seems to
depend on the location of the neuropathological changes, and
in particular on the neuroanatomical distribution of TDP-43
pathology, rather than to the presence of specific pathological
aspects. UMNs and LMNs together with the frontotemporal
cortex and subcortical regions are most vulnerable to ALS
pathology. However, neurodegeneration progresses to different
areas including the amygdala, substantia nigra, and striatum (47),
and it is potentially explained by the cell-to-cell spread of the
disease, similar to what is seen in prion disease (48, 49).
The exact mechanisms of TDP-43-induced cell death are
currently unclear. Reduced TDP-43 seems to induce defect in
cell proliferation rather than directly cause cell death. However,
overexpression of wild-type and mutant TDP-43 can induce
p53-dependent apoptosis of neuronal progenitors and TDP-43
per se can promote the expression of proapoptotic genes. In
mouse models, cytoplasmic mislocalization of TDP-43 induces
apoptosis even in the absence of aggregates. In addition, aberrant
TDP-43 alters splicing and RNA metabolism. Finally, aggregates
of hyperphosphorylated and fragmented TDP-43 protein are
associated with stress responses and facilitate cell death (50).
In particular, TDP-43 has a fundamental role in regulating the
survival of motor/cortical neurons and astrocytes through its
effects on stress granules, which facilitate cell survival in course
of exposure to stress (51). These aspects are the basis of the
significant cortical degeneration/dysfunction observed in ALS.
In particular, the prominent TDP-43 accumulation in cortical
neurons is directly connected with cortical dysfunction. The
most vulnerable structures are: the pyramidal cells in layer Vb
of M1; large alpha motor neurons of the lower brainstem and
spinal cord; projection neurons of the striatum; parvocellular red
nucleus; inferior olive; and motor nuclei of the V, VII, XI, and
XII cranial nerves. The subsequent diffusion through corticofugal
projections underlines the primary involvement of the cerebral
cortex (13).
Link to Hyperexcitability
Hyperexcitability substantially originates from reduced threshold
to respond to a stimulus, or exaggerated response to a
suprathreshold stimulus, being it referred to individual cells or
entire cortical networks.
Investigations on gene expression in the cortex from
ALS patients or mouse models revealed a wide series of
transcriptomic alterations involving channels, transporters, and
receptors. Specifically, these abnormalities concern Na+/K+
ATPase, voltage-gated Na+, and K+ channels, K+/Cl− co-
transporter, ionotropic and metabotropic glutamate receptors,
glutamate transporters, and GABA receptors [reviewed in
Brunet et al. (52)]. Such alterations account for dysfunction
of individual cell excitability and of excitatory and inhibitory
synaptic transmission.
Excessive response to stimuli of cortical cells is sustained by
ion channel dysfunctions. In particular, persistent Na+ currents
together with reduction of K+ conductance lead to an imbalance
of ion channels, which finally increases membrane excitability
(35). Another crucial aspect of cortical hyperexcitability is the
reduced glutamate clearance by astrocytes, which seems to
cause motor neuron overstimulation and consequently neuronal
degeneration, possibly through increased Ca2+ concentration
(35). Indeed, increased Ca2+ flux through glutamate receptors
and activation of voltage-gated channels are crucial in
determining excitability of motor neurons, which are particularly
sensitive to Ca2+ levels (53). Astrocytes might also favor cortical
hyperexcitability through dysregulation of potassium clearance,
which leads to extracellular K+ accumulation and consequently
membrane depolarization and increased excitability (35). In
cultured cortical neurons, increased extracellular Na+, Ca2+,
K+, and Cl− levels lead to hyperexcitability and increase of
dendritic spines, thus supporting the role of these changes in
inducing early toxicity (54).
A major role in UMN overstimulation is currently attributed
to the impairment of cortical inhibitory circuits due to the
involvement of GABAergic interneurons, which alters GABA
receptor-mediated inhibitory currents and facilitates motor
neuron degeneration (35, 55). Pre- and post-synaptic glycine
receptors, which mediate synaptic inhibition, are also involved
in motor neuron/interneuron dysfunction (56). GABAergic
interneurons account for 20–25% of all neocortical neurons
and can be distinguished, based on non-overlapping molecular
markers, in three main groups that also show specific synaptic
Frontiers in Neurology | www.frontiersin.org 4 February 2021 | Volume 11 | Article 605335
Ranieri et al. Neuromodulation in ALS
connections to layer V pyramidal cells: (1) parvalbumine (PV)-
positive neurons, representing the largest interneuron population
in the neocortex, include two subgroups projecting, respectively,
to axon initial segment and to soma or proximal dendrites
of pyramidal cells; (2) somatostatine (SST)-positive neurons
receive strongly facilitatory inputs and project to apical dendrites
of pyramidal cells; and (3) 5HT3AR-positive neurons, further
divided into vasointestinal peptide (VIP)-positive neurons,
providing inhibitory input to SST+ cells, and VIP-negative
neurons, connected to the soma or dendrites of pyramidal
cells through GABAA or GABAB receptors (57). These cell
populations can be affected in ALS in terms of cell loss (58, 59) or
altered excitability (60). Interestingly, in a TDP-43 mouse model,
it has been observed that hyperactivity of SST+ interneurons
can be responsible for hyperexcitability of layer V pyramidal
cells through inhibition of PV+ interneurons (60). Moreover, a
demonstration of degeneration of PV+ interneurons along with
reduced expression of GABAA receptor alpha-1 subunit in ALS
patients can account for reduced intracortical inhibition (i.e.,
SICI), as tested by TMS (30). Moreover, increasing the activity
of hypoactive PV+ interneurons in a SOD1-G93A mouse model
was recently demonstrated to reduce CSN hyperexcitability and
to delay the onset of motor deficits (61).
At a circuit level, the activity of CSNs and interneurons is
regulated by several afferent projections from distant structures
by means of different neurotransmitters. Neuropathological
studies on both ALS patients and mouse models have shown
impairment of serotoninergic, dopaminergic, noradrenergic,
histaminergic, and cholinergic systems, variably characterized by
loss of neurons, altered expression of transporters and receptors,
or TDP-43 inclusions [reviewed in Brunet et al. (52)]. However, it
is not defined to which extent each of these alterations of cortical
afferents might contribute to motor cortical hyperexcitability.
Altogether, the above dysfunctions contribute to
overactivation of CSNs, which can subsequently induce the
degeneration of spinal motor neurons. In addition, it has been
recently demonstrated that neuronal hyperactivity leads to the
upregulation and accumulation of a highly insoluble isoform of
TDP-43 within neurons and glia, supporting the hypothesis of
an upstream pathogenic role of hyperexcitability in ALS (2).
Synaptic Dysfunction
As in other neurodegenerative conditions, synapse degeneration
is a crucial aspect of ALS. In mouse models, mutated TDP-
43 pathological accumulation alters dendritic spine density and
causes synaptic alterations leading to excitability dysfunction and
finally, neuronal damage (62).
In human post-mortem tissues, high sensitive analyses
allowed to demonstrate that synapse loss occurs also in the
absence of neuron loss. Despite the exact cause of synapse
loss is unknown, it could be due to accumulation of TDP-43
aggregates into spines and/or to direct phagocytosis mediated
by activated microglial cells (63). The alteration of dendrite
and synapse formation/morphology leads to accumulation of
glutamate with subsequent overactivation of glutamate receptors,
which finally promotes the cell death cascade. In support of
the relevance of these pathological changes, recent therapeutic
approaches besides riluzole, proposed for clinical trials, target
synaptic alterations and, specifically, receptors, ion channels, and
hyperexcitability (64).
TARGETS OF BRAIN STIMULATION
TECHNIQUES
Different non-invasive brain stimulation methods have been
evaluated in ALS with the purpose of producing persistent
modulatory effects on neural activity by interfering with
mechanisms of cortical motor neuron hyperexcitability.
Invasive epidural cortical stimulation was also tested for
chronic administration. While these interventions share the
effect of an overall reduction of the corticospinal output
to subsequent depolarizing inputs, which might prevent
excitotoxicity, we have now sufficient knowledge on specific
underlying mechanisms characterizing different types and
paradigms of brain stimulation. Focusing on the interaction
of brain stimulation with specific mechanisms characterizing
hyperexcitability in ALS might represent the proper way
toward targeted neuromodulatory interventions with increased
therapeutic potential.
Among techniques of non-invasive brain stimulation, rTMS
produces long-lasting effects on synaptic transmission by
repeated synaptic activation following depolarizing inputs (65),
and inhibitory (LTD-like) effects can be obtained with either
low-frequency (e.g., 1Hz) stimulation (66), patterned paradigms
such as the continuous theta burst stimulation (cTBS) (67), or
paired associative stimulation protocols (68). Instead, tDCS acts
by producingmembrane depolarization/hyperpolarization that is
subthreshold for evoking action potentials but that can influence
the neuron spontaneous firing frequency (69) and long-term
potentiation (LTP)/long-term depression (LTD) mechanisms of
synaptic plasticity (70–72).
Recordings from the corticospinal tract in intact human
subjects through implanted epidural electrodes provided
insight into the site of action of different protocols of brain
stimulation (73). Indeed, the corticospinal discharge represents
a direct measure of the M1 output being not influenced
by spinal excitability. It is then possible to test the effect of
neuromodulatory interventions on the corticospinal activity
generated by single TMS pulses with known patterns of activation
of corticospinal circuits. Specifically, depending on how M1 is
activated with single-pulse TMS, the descending corticospinal
volley can be composed of the following: (1) a very early
wave generated by the direct activation of corticospinal axons,
hence termed “D wave;” (2) an indirect “I1 wave” generated by
monosynaptic activation of CSNs; and (3) one or more later I
waves generated by the transsynaptic activation of CSNs at a
greater distance from the cell body or by reverberating activity of
a local intracortical circuit [reviewed in Di Lazzaro et al. (16)].
Corticospinal recordings, as a first point, confirm the
cortical origin of LTP-/LTD-like effects produced by brain
stimulation, since they demonstrate changes in the composition
and amplitude of the descending corticospinal volleys generated
by the activation of cortical circuits. Additionally, effects on
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individual components of the corticospinal volley, generated by
direct activation of CSNs or by the indirect activation of CSNs
through corticocortical projections, point to specific sites of
action of rTMS and tDCS protocols [reviewed in Di Lazzaro and
Rothwell (73)].
Most NIBS protocols selectively modulate the later I waves,
indicating a modulatory effect either on interneurons connected
to CSNs (74) or on a reverberating local circuit within M1,
composed of interconnected layer II/III excitatory intracortical
pyramidal neurons, layer V pyramidal tract neurons, and
GABAergic interneurons (75).
This is the case of most inhibitory paradigms, such as
1-Hz rTMS (76), paired associative stimulation (PAS) at an
interstimulus interval (ISI) of 10ms (77), and cathodal tDCS (78).
Some facilitatory paradigms, such as intermittent TBS (iTBS)
and PAS at an ISI of 25ms, show the same pattern of cortical
interaction though in an opposite direction (79, 80). Differently,
the inhibitory cTBS protocol selectively reduces the I1 wave: this
indicates that it affects the excitability of the initial monosynaptic
input to CSNs (81).
Interestingly, while an effect on later I waves has been
demonstrated for both cathodal (inhibitory) and anodal
(facilitatory) tDCS, anodal tDCS also showed facilitation of the
I1 wave (78) and of the D wave (82); the latter finding indicates
increased excitability of corticospinal axons and this was not
tested with cathodal tDCS. Since the effects of tDCS on cortical
plasticity are polarity-specific and are likely to be primed by
depolarizing/hyperpolarizing effects on neuronal membrane
(83), it can be hypothesized that cathodal tDCS also has a direct
modulatory effect on corticospinal axons in analogy with anodal
tDCS but in the opposite direction.
Moreover, a comparison of descending volleys evoked by
transcranial and epidural motor cortex stimulation indicates that
epidural stimulation can produce repetitive excitation of CSNs
similar to TMS (84), supporting the use of epidural stimulation to
modulate cortical excitability in the same way as rTMS protocols,
even if the effect of prolonged stimulation on corticospinal
descending activity was not investigated.
Figure 1 summarizes the proposed sites of interaction
of different stimulation techniques within intracortical and
corticospinal circuits affected by ALS.
It must be considered that the effects of modulatory
interventions on corticospinal activity were measured in a
small number of subjects: this limits the level of certainty of
proposed models of interaction of different brain stimulation
protocols with motor cortical circuits. However, based on current
evidence, we can expect that certain types of interventions
suppressing M1 excitability, such as cTBS, will mainly affect
excitatory intracortical inputs to layer V pyramidal cells,
while other protocols, such as 1-Hz rTMS, PAS, and cathodal
tDCS, will affect more complex intracortical circuits including
GABAergic interneurons connected to layer V pyramidal
cells. Moreover, based on the biophysical properties of the
technique and on very preliminary data, it is conceivable
that tDCS has also some direct modulatory effect on CSN
excitability in addition to its interaction with synaptic plasticity
(85, 86).
THERAPEUTIC TRIALS IN ALS
A systematic search for original studies applying brain or spinal
stimulation on ALS subjects, with the purpose of persistent
neuromodulation aimed at affecting functional status, was
performed on 10th August 2020 in the PubMed database
(U.S. National Library of Medicine, NIH), using the following
search terms:
#1 [als amyotrophic lateral sclerosis (MeSH Terms)] OR [motor
neuron disease (MeSH Terms)] OR [amyotrophic lateral
sclerosis (Title/Abstract)] OR [ALS (Title/Abstract)];
#2 [transcranial magnetic stimulation (MeSH Terms)];
#3 [electrical stimulation of the brain (MeSH Terms)];
#4 [magnetic field therapy (MeSH Terms)];
#5 [stimulation (Title/Abstract)];
#6 {[magnetic (Title/Abstract)] AND [repetitive
(Title/Abstract)]} OR [current (Title/Abstract)] OR
[electrical (Title/Abstract)] OR [epidural (Title/Abstract)]
OR [spinal (Title/Abstract)] OR [focused ultrasound
(Title/Abstract)] OR [static magnetic field (Title/Abstract)];
#7 [TMS (Title/Abstract)] OR [tDCS (Title/Abstract)] OR
[tACS (Title/Abstract)]
Combined query: #1 AND [#2 OR #3 OR #4 OR (#5 AND #6)
OR #7].
Query produced 431 results, which were screened on the basis
of title and abstract; 28 remaining full-text articles were assessed
for eligibility; 14 original studies were included in qualitative
synthesis (summarized in Table 1).
Repetitive Transcranial Magnetic
Stimulation
Most therapeutic trials employed rTMS with paradigms of
stimulation known to have inhibitory effects on motor cortical
excitability. In particular, cTBS was tested in four studies by Di
Lazzaro et al. In a first randomized trial on 20 ALS patients, active
bilateral cTBS of M1 delivered for 5 days/month was associated
with slowing of disease progression after 6 months of treatment
(88). This finding was not replicated in a following trial in which
the duration of cTBS treatment was extended to 12 months (90).
Of note, in a further small study by the same group (93) in which
the dosage of cTBS was doubled to 10 days/month, a tendency
to a slower progression over 6 months was observed when
comparing with pooled data of patients treated for 5 days/month
and of “sham”-treated patients from the previous studies (88, 90),
even if it was not possible to demonstrate a reduction from
baseline progression in this new patients’ group (93). The other
two studies with cTBS are small case series in which stimulation
was delivered for a prolonged period of >2 years in one subject
(91) or for a period of 1 year as an “open-label” extension
study of previous trial in three subjects who had been observed
for 1 year under placebo stimulation (92): in both cases, a
reduction of ALSFRS-R score was observed in comparison with
baseline observation. One study (101) confirmed, in a sample of
10 ALS subjects, the physiological inhibitory effect of cTBS on
M1 excitability observed in the healthy population, by showing
a cumulative increase of motor threshold and a reduction of
Frontiers in Neurology | www.frontiersin.org 6 February 2021 | Volume 11 | Article 605335
Ranieri et al. Neuromodulation in ALS
FIGURE 1 | Schematic representation of mechanisms implicated in the origin of hyperexcitability in ALS and of proposed sites of interaction of different techniques of
stimulation of the corticospinal system. Excitatory glutamatergic input to upper motor neurons (UMN, red) is mainly provided by upstream layer 2 and 3 pyramidal
(Continued)
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FIGURE 1 | neurons (L2/3, light blue) and modulated by astrocytes (AS, green). Different populations of interneurons (IN, black) provide GABAergic input within M1 (a
single simplified connection to UMN apical dendrite is represented). All the above cell groups and synaptic connections can be affected by ALS pathophysiological
alterations, and current evidence suggests an interplay between functional and molecular alterations, such as TDP-43 cytoplasmic accumulation. It is proposed that
most NIBS protocols selectively modulate bursting cells of layers 2 and 3 that project upon layer 5 pyramidal cells or a reverberating local circuit within M1 including
GABAergic interneurons; cTBS selectively suppresses the excitability of monosynaptic connections to CSNs; 5-Hz rTMS may produce its effects by enhancing the
excitability of CSNs; anodal tDCS and other invasive and non-invasive spinal stimulation techniques interact with corticospinal axons. Stimulation protocols with a
documented inhibitory effect on corticospinal excitability are indicated in blue. Histological insert shows TDP-43 skein-like inclusions in the cytoplasm of motor
neurons of the hypoglossal nuclei in the medulla oblongata (×100 original magnification). Neuromodulation techniques—rTMS, repetitive transcranial magnetic
stimulation; tDCS, transcranial direct current stimulation; iTBS/cTBS, intermittent/continuous theta burst stimulation; PAS, paired associative stimulation.
MEP amplitude over 5 days of M1 stimulation, supporting the
rationale for testing this kind of stimulation in ALS.
One earlier pilot study tested both low-frequency (1Hz) rTMS
in two subjects and high-frequency (20Hz) rTMS in two subjects
(87): the rationale for using high-frequency stimulation, with
an excitatory effect on M1, was provided by another study that
showed that 20-Hz rTMS can induce an increase of brain-derived
neurotrophic factor (BDNF) blood level (102). However, only
1-Hz rTMS was associated with slowing of disease progression
over more than 2 years of treatment, while 20-Hz rTMS did not
determine any reduction in baseline progression, which instead
had an acceleration in the two treated patients, and it was
therefore discontinued within 3 months. The latter finding could
be explained by the fact that high-frequency rTMS enhances
the activation of non-NMDA glutamatergic receptors within
the motor cortex (103) with a consequent potentiation of non-
NMDA-mediated glutamatergic excitotoxicity (104).
Another pilot controlled trial tested 5-Hz rTMS, delivered
to M1 bilaterally for 2 weeks, in five ALS subjects (89). The
rationale behind the use of this frequency of stimulation was
looking for a compromise between the supposed detrimental
cortical excitatory effect and protective BDNF-release-facilitating
effect of high-frequency rTMS (102). A transitory improvement
of muscle strength and quality of life was observed in the treated
group; however, this effect was no longer evident 2 weeks after
discontinuation of rTMS.
Non-invasive Electrical Stimulation
Non-invasive techniques using electrical stimulation encompass
tDCS and transcutaneous spinal stimulation. At present, other
techniques of brain stimulation using a variable current intensity,
such as transcranial alternating current stimulation (tACS), have
not been employed in therapeutic trials in ALS.
In the last decade, tDCS was tested mainly in the attempt of
obtaining a portable therapeutic option that does not require to
be delivered within the hospital setting. Indeed, tDCS requires
only a small size stimulator and it can be delivered even at
patients’ home.
To date, the number and size of tDCS studies is overall even
smaller than that of rTMS studies. In the only study (94) in which
cathodal tDCS of M1 was delivered for a prolonged time in a
single subject, no effect on disease progression was observed. This
was also the case of a single patient reported by Madhavan et al.
(96), treated for 4-week periods with either anodal, cathodal, or
sham tDCS, and of two patients reported by Sivaramakrishnan
et al. (97), treated for 8 weeks with anodal tDCS of M1. The
latter study also evaluated the feasibility of remotely supervised
treatment, with therapists guiding caregivers through internet in
the application of tDCS and reporting of adverse events.
From a physiological point of view, Munneke et al. (105) had
failed to induce a consistent decrease in corticospinal excitability
in ALS patients, compared to healthy controls, following a single
session of 1-mA cathodal tDCS over M1.
Recently, Benussi et al. (95) tested a more complex tDCS
paradigm, consisting in concurrent bi-anodal motor cortex and
cathodal spinal stimulation (i.e., corticospinal tDCS), in the
attempt to obtain a synergic effect from the stimulation of both
structures. Thirty patients were recruited using a randomized
controlled trial design. A significant improvement/stabilization
in clinical scores of muscle strength, in quality of life scores,
and in caregiver burden was observed after 2-week treatment
with real tDCS applied 20 min/day at an intensity of 2mA.
Interestingly, these effects persisted at 6 months after the end of
treatment and were paralleled by restoration of TMS parameters
of intracortical circuit excitability (i.e., SICI and ICF). However,
it must be observed that a slower-than-usual disease progression,
as expressed by a decline of ALSFRS-R score of <2 pts over
6 months, characterized both real and sham tDCS groups. A
further clinical trial by the same group is ongoing, with the aim of
assessing stabilization of improvement after repeated treatment
(ClinicalTrials.gov ID: NCT04293484).
A recent feasibility neurophysiological study (106) also
confirmed the possibility of activating spinal motor neurons
both trans-synaptically and non-synaptically, at axonal level,
with cervical transcutaneous constant-current stimulation,
supporting the possibility of using non-invasive tools for
targeting spinal pathophysiological mechanisms of ALS. A pilot
study is currently active in ALS to expand the investigation
on the interaction of cervical transcutaneous stimulation
with other central and peripheral circuits and with circuits
involved in volitional limb movement (ClinicalTrials.gov
ID: NCT03411863).
Invasive Stimulation Methods
Invasive cortical or spinal stimulation might represent an
interesting translational prospect of preliminary findings
obtained non-invasively into therapeutic strategies based on
increased stimulation dosage. However, to date, only very
few cases of ALS patients with implanted stimulators have
been reported.
Cortical subdural stimulation was initially tested by Sidoti
and Agrillo (98) in four patients who underwent bilateral M1
























TABLE 1 | Summary of studies applying brain or spinal stimulation with the purpose of producing persistent effects on functional status in ALS.
Design Protocol Site Dosage Duration N Control Riluzole Outcome Main findings
rTMS studies
Di Lazzaro et al. (87) Pilot 1Hz M1 (L + R) 10 d/4m 25, 30m 2 No No Norris, MRC Slowed progression (Norris, MRC)
Di Lazzaro et al. (87) Pilot 20Hz M1 (L + R) 8 d/m 2, 3m 2 No Yes Norris, MRC No detectable effects
Di Lazzaro et al. (88) RCT cTBS M1 (L + R) 5 d/m 6m 20 Yes Yes ALSFRS-R, MRC Slowed progression (ALSFRS-R)
Zanette et al. (89) RCT 5Hz M1 (L + R) 5 d/w 2w 10 Yes Yes ALSFRS-R, MRC,
MVIC (grip), FSS
(fatigue), SF-36 (QoL)
Improved grip strength and QoL at the end of treatment, not
significant at 2 weeks after the end of treatment
Di Lazzaro et al. (90) RCT cTBS M1 (L + R) 5 d/m 12m 20 Yes Yes ALSFRS-R, MRC No significant effects
Di Lazzaro et al. (91) Pilot cTBS M1 (L + R) 5 d/m 26m 1 No Yes ALSFRS-R Slowed progression
Di Lazzaro et al. (92) Open
label
cTBS M1 (L + R) 5 d/m 5, 10,
12m
3 No Yes ALSFRS-R, Resp.
failure
Slowed progression compared with previous 1-year period of
observation
Di Lazzaro et al. (93) Pilot cTBS M1 (L + R) 10 d/m 12m 5 No n/a ALSFRS-R No significant effects vs baseline progression. Slower
progression than control patients and possibly slower
progression than patients treated 5 d/m over 6 months in a
pooled analysis with data from Di Lazzaro et al. (88) and
Di Lazzaro et al. (90)
tDCS studies
Di Lazzaro et al. (94) Pilot c-tDCS M1 (L + R) 1mA, 20min; 5
d/m
1, 12m 2 No n/a ALSFRS-R, Resp.
failure
No detectable effects (1 patient died after 1 month of treatment)





2w 30 Yes Yes ALSFRS-R, MRC,
ALSAQ-40, EQ-5D,
EQ-VAS, CBI
Improvement/stabilization in MRC, EQ-VAS, CBI clinical scores
Madhavan et al. (96) Pilot a-c-sham-tDCS M1 (L) 2mA, 20min; 3
d/w





Pilot a-tDCS M1 (R) 2mA, 20min; 3
d/w





Sidoti and Agrillo (98) Pilot Subdural ES
(30Hz)
M1 (L + R) Continuous 2 y 4 No n/a ALSFRS Slowed progression in 2 out of 4 patients
Di Lazzaro et al. (91),
Di Lazzaro et al. (99)
Pilot Epidural ES
(3Hz; 30Hz)
M1 (L + R) Continuous >3 y 1 No n/a ALSFRS-R No effect on disease progression in the first 2 years of treatment.
Survival at 12 years after prolonged epidural ES treatment




Continuous 10m 1 No Yes ALSFRS-R No detectable effects
Study design—RCT, randomized controlled trial. Stimulation protocols—cTBS, continuous theta burst stimulation; a/c-tDCS, anodal/cathodal tDCS; ES, electrical stimulation. Stimulation dosage/duration—d, day(s); m, month(s); w,
week(s); y, year(s). Functional outcome measures—ALSFRS(-R), ALS functional rating scale (revised); MRC, muscle strength measured with the Medical Research Council scale; MVIC, maximum voluntary isometric contraction; FSS,
fatigue severity scale; SF-36, MOS 36-Item Short Form Survey; ALSAQ-40, ALS assessment questionnaire; EQ-5D, EuroQol 5 dimensions; EQ-VAS, EuroQol visual analog scale; CBI, caregiver burden inventory; 6MWD, 6-min walking
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stimulation for up to 2 years: a slowing of ALS progression was
observed in two of them, while one committed suicide. Based
on this experience, Di Lazzaro et al. (99) treated one subject,
showing prominent upper motor neuron involvement at disease
onset and a rapidly progressive course, with bilateral epidural
M1 stimulation delivered for more than 3 years: while he did
not show substantial changes in disease progression in the first
2 years, as measured with the ALSFRS-R, he was still alive at 12
years and he neither required continuous ventilatory support nor
gastrostomy for about 10 years. The benefit of epidural motor
cortical stimulation was confirmed in a SOD1-G93A murine
model of ALS (107).
The effects of epidural spinal stimulation in ALS have been
investigated by Di Lazzaro et al. (100) in one subject affected
with a typical spinal-onset form of ALS. This subject was
observed clinically for 10 months after starting cervical epidural
spinal stimulation for the treatment of chronic cervico-dorso-
lumbar pain: while high-frequency stimulation was effective
in controlling pain, indicating that spinal cord circuits were
effectively activated and modulated, it did not modify ALS
progression compared to that before intervention.
Safety Considerations
The studies analyzed above, including a total of <100 ALS
patients undergoing active treatments with either rTMS, tDCS,
or invasive subdural/epidural stimulation, did not report any
adverse event. Mild dysesthesias under tDCS electrodes might
be perceived (97). It must be noticed that, since studies did not
investigate systematically the occurrence ofmild collateral effects,
e.g., using specific questionnaires, some of the most common
mild effects already described in the guidelines on the use of
rTMS and tDCS (108, 109), such as headache, might have not
come to researchers’ attention. It must also be considered that
people affected with ALS have a usually high expectation for some
efficacy of the proposed treatment; therefore, they might not pay
enough attention to very mild collateral symptoms.
Seizures are the most feared adverse event with non-invasive
brain stimulation, although they are a rare event. No seizures
have been reported in the above-analyzed studies with ALS
patients. Inhibitory rTMS and tDCS protocols are traditionally
considered at lower risk of inducing seizures. A recent analysis
on more than 300,000 TMS sessions (110) indicates that, when
TMS is delivered within published guidelines (108), seizures
have no higher incidence with high-frequency rTMS protocols
than with low-frequency and single-pulse protocols, being
it very low (∼0.02/1,000 TMS sessions); otherwise, the risk
is increased in subjects with other risk factors (∼0.33/1,000
TMS sessions). In ALS patients, the effort toward increasing
stimulation dose to strengthen therapeutic effects could lead
to exceeding current safety limits: this might determine an
increased risk of seizures, especially with continuous delivering
of cortical epidural stimulation. However, given the low absolute
risk of seizures in subjects without other risk factors (110), it
is foreseeable that, if a higher stimulation dosage is proven to
determine a clinically significant effect, the therapeutic window
will be large enough to allow a more intensive intervention.
Pauses between stimulation sessions could also help to reduce the
risk of seizures.
Finally, due to the relatively short time of observation and
the small number of recruited patients in ALS trials, long-term
effects of prolonged brain stimulation procedures could not
be investigated.
MEASURING THE EFFECTS OF
THERAPEUTIC INTERVENTIONS
Measuring the effects of new therapeutic interventions in
ALS is challenging. Besides survival, requiring large samples,
and long trials, more selective indices of disease course are
usually employed to increase sensitivity in small trials. However,
distinct measures have a different sensitivity in catching
specific functional and pathophysiological alterations that can be
differentially affected during disease progression.
In this section, we summarize the main outcome
measures that can be used to assess the response to
neuroprotective interventions based on brain stimulation
techniques, ranging from functional clinical scales measuring
the overall level of disability to neurophysiological tools




Initial attempts for developing a functional rating scale were
pursued in the 1970s, namely, the Norris Scale and its modified
version that consists of two parts, i.e., the Limb Norris Score,
composed of 21 items, and the Norris Bulbar Score, composed
of 13 items (111). However, both scales were complex and time
consuming to administer. Thus, in the 1990s, the most well-
known and utilized measure of disease progression, the ALS
functional rating scale (ALSFRS), was developed (112). Few years
later, the original ALSFRS was replaced with the ALSFRS-revised
(ALSFRS-R) when it was recognized that additional measures of
respiratory decline were needed (113). The new scale consists of
12 items (highest score: 48) encompassing three main domains:
bulbar function, fine and gross motor abilities, and respiration.
An extended version of the ALSFRS-R (ALSFRS-EX) has also
been proposed to improve its sensitivity at lower levels of physical
function in patients in an advanced stage, by adding three items
to ALSFRS-R relating to the ability to use fingers, to show
emotional expression in the face, and to get around inside the
home (114).
ALSFRS-R is largely used in several clinical trials, it is easy
to perform remotely for telehealth, and its self-administered
version shows good reliability and sensitivity to change over
time vs. the standard evaluator-administered ALSFRS-R (115).
However, this scale has several limitations that should be
acknowledged (Table 2). A recent Rasch analysis found that the
test failed rigorous measurement standards, with the authors of
this analysis calling for its revision (116). Lastly, the ALSFRS-
R score largely reflects disability due to muscle wasting, mostly
representing the LMN involvement; therefore, it neglects clinical
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ALSFRS-R • Easy to employ, can be self-administered and used remotely for
telehealth
• Has been shown to correlate to survival and is robust in several trials
• Relatively insensitive to progression over short periods of time
• Affected by mood/effort
• Neglects clinical spectrum of UMN damage
King’s system • Easy to employ
• Good estimation of disease progression, especially in early
to mid-disease
• Ordinal scale
• Low clinical resolution
MiToS staging systems • Easy to employ
• Good estimation of disease progression, especially in late stages
• Ordinal scale
• Low clinical resolution
Muscle strength
MRC • Easy to use in clinical setting
• Good overview of muscle wasting pattern
• Subjective, affected by the mood of both patient and examiner
• Not sensitive to disease progression
• Ordinal scale
• Poor reproducibility
• Not able to distinguish weakness due to LMN vs. UMN
Quantitative testing
(dynamometer)
• Reliable and sensitive indicator of disease progression
• Good reproducibility
• Objective measure
• Usually limited to hand muscles
• Not able to distinguish weakness due to LMN vs. UMN
Respiratory function
FVC • Quantifies the health of the most critical activity for sustaining life
• Repeatable
• Only evaluates a single region
• May not show changes early in disease course
• Later in disease, it may be affected by bulbar weakness and
poor lip closure
Cognition
ECAS, ALS-CBS, BBI • Validated screening instruments
• Objective measures of cognitive decline
• Language and fluency scores can be partly biased by reduced
fine motor skills and/or speech impairments
• Require specialized equipment and training
Neurophysiological measures
UMN dysfunction
TMS: CMCT • Easy to use in clinical setting
• Can be used in multicenter studies
• Affected by muscle wasting
• Not accurate for early UMN dysfunction
• Not sensitive enough for proximal muscles
TMS: threshold
tracking method
• Good biomarker in the assessment of UMN dysfunction
• Monitor the effects of new drugs on UMN
• Requires specialized equipment and training
• Few normative data available
• Limited to distal muscles
• Not able to capture proximal muscle involvement
• May be challenging to use in multicenter studies
TMS: TST • Allows a good estimation of the proportion of lost UMNs supplying the
target muscle
• TST reductions are more common than abnormalities of conventional
MEP (i.e., prolonged CMCT or reduced MEP amplitude)
• Quite painful
• Few normative data available
• Cannot be performed to proximal muscles
• Requires specialized equipment and training
• May be challenging to use in multicenter studies
LMN dysfunction
CMAP • Easy to obtain
• Can be used in multicenter studies
• Limited to distal muscles
• Not able to capture proximal muscle involvement
• Insensitive in assessing LMN degeneration due to reinnervation
NI • Easy to obtain, requires no special equipment
• May be very sensitive to LMN loss, even in pre-symptomatic stage
• Sensitive indicator of disease progression
• Limited to distal muscles
• Not able to capture proximal muscle involvement
• Requires persistent F-waves
• Few normative data are available
MUNE/MUNIX • Sensitive to LMN loss, even with stable CMAP amplitudes
• Provides approximation of actual motor neuron number and rate of
actual motor neuron loss
• Technically challenging
• Limited to distal muscles
• Not able to capture proximal muscle involvement
• Low repeatability especially at the early stage of disease
F-wave • Indirect measure of spasticity
• Good measure of LMN excitability
• Limited to distal muscles
• Not able to capture proximal muscle involvement
• Correlates poorly with clinical deficit
• Usually requires an adequate CMAP amplitude
(Continued)
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• Provides information about peripheral axonal excitability
• Potentially useful for early diagnosis
• Good biomarker of therapeutic effectiveness
• Correlates with survival
• Limited data on progression
• Requires specialized equipment and training
• May be challenging to use in multicenter studies
• Varies a lot among axons in a single nerve
• Limited to upper limbs
spectrum of UMN damage. To obtain a more specific scale of
UMN involvement, patients can be also graded in terms of UMN
“burden,” by totaling the number of pathological UMN signs on
examination, such as brisk upper and lower limb reflexes and
brisk facial and jaw jerks (highest score: 16) (117). Additional
scores for UMN degeneration are the Penn UMN Score (118,
119), measuring also pseudobulbar symptoms by considering
the Center for Neurologic Study-Lability Scale (CNS-LS) (120),
and muscle tone by means of the Modified Ashworth scale
(MAS) (121).
Importantly, over the last few years, two functional scales
[the King’s College and Milano-Torino Staging (MiToS) staging
systems] have been proposed to staging ALS. The King’s College
system uses five stages, ranging from 1 being symptom onset
and stage 5 being death, and relies on the clinical spread of
disease among the several clinical regions as a measure of
progression (122). Instead, the Milano-Torino Staging (MiToS)
(123) utilizes the subscores produced by the ALSFRS-R to define
stage, with stage 0 being normal function and stage 5 being
death. A recent comparison analysis suggested that the two
systems are complimentary, with King’s staging showing greatest
resolution in early to mid disease and MiToS staging having
higher resolution for late disease (124).
Muscle Strength
Loss of muscle strength is a cardinal feature of ALS. Functional
loss over time, including respiratory dysfunction, inability to
ambulate, loss of ability to perform activities of daily living, and
others are due, in large part, to decline in strength. Therefore, the
accurate measurement of limb muscle strength and respiratory
function is essential in therapeutic trials to better understand the
impact of therapy on vital function.
With regards to limb muscle strength evaluation, we have a
qualitative assessment with the manual muscle testing (MMT)
scale established by the Medical Research Council of the
Royal College of Physicians and Surgeons (MRC), scoring
from 0 (paralysis) to 5 (normal strength) each tested muscle.
However, the measure itself is subjective; therefore, to overcome
such limitations, quantitative scales have been developed (i.e.,
muscle strength evaluation with dynamometer), and with
careful training and reliability testing, they have proven to
be reliable and sensitive indicators of disease progression.
The ability to determine objectively the source of weakness
would be of great value and should be a subject of future
research (125).
Respiratory Function
Respiratory failure is the primary cause of death in ALS.
Interestingly, approximately in 3–5% of cases, ALS can begin with
respiratory failure (126–128). Change in respiratory performance
is indicative of ALS progression, since respiratory function is
directly related to skeletal muscle function and survival (129).
According to American (130) and European guidelines
(131), all ALS patients should perform regularly after diagnosis
spirometry measurements, such as forced vital capacity
(FVC). Other recommendations include nocturnal pulse
oximetry, polysomnography, arterial blood gases, maximal
inspiratory/expiratory pressure, sniff nasal pressure, or trans-
diaphragmatic pressure if patients are symptomatic and FVC is
>50% (132). The inclusion of these tests, in addition to FVC,
may assist in detecting changes in respiratory function early in
the disease course (133) and leading to institution of supportive
therapy with non-invasive ventilation (130, 131).
Cognition
Although motor system deficits may appear prominent, ALS is
increasingly recognized as a multisystem disorder accompanied
by cognitive changes (128).
In contrast to the relentlessly progressive motor deficits, the
trajectory of cognitive and behavioral deficits is less clear due to
considerable individual variations, genotype-associated profiles
(134, 135), differences in assessment strategies, and practice
effects (136). Importantly, recent evidence has pointed out that
up to 30–50% of ALS patients show cognitive impairment,
ranging from frontotemporal dementia to milder forms of
executive or behavioral dysfunctions (128). The impairment of
cognitive functions is a relevant negative prognostic risk factor,
independent from other known factors such as age, site of
onset, diagnostic delay, disease severity, and respiratory function
(137, 138). In addition, cognitive impairment can be present at
diagnosis as well as manifest during the disease (139), and it
might get worse in parallel with motor deterioration (140), and
patients with respiratory compromise are more likely to develop
reduced cognitive function (141).
Cognitive and behavioral domains are routinely assessed
thanks to validated screening instruments such as the Edinburgh
Cognitive and Behavioral ALS Screen (ECAS) (142), the
Beaumont Behavioral Inventory (BBI) (143), and the ALS
Cognitive Behavioral Screen (ALS-CBS) (144).
Survival and Combined Assessments
Since ALS is characterized by progression to death, survival is
recommended as the primary endpoint for phase 3 trials (145).
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Indeed, the approval of the first drug for ALS, riluzole, was based
on survival data (4).
Survival analysis, in its wider conception, encompasses
approaches to investigate the time for an event of interest
to occur and is largely based on Kaplan–Meier estimates.
Since the time to death in ALS is extended by nutritional
and respiratory interventions, some trials included time to
tracheostomy or prolonged non-invasive ventilation as part of
survival outcome, but the use of respiratory interventions differs
between centers and it could even increase variability of these
combined measures (145).
Considering that survival time in ALS is quite variable, in
order to reach a sufficient statistical power, the two fundamental
requirements are that (a) the time of observation must be long
enough relative to the average disease course and (b) the groups
must be large enough to overcome intrinsic variability and
appreciate differences. Survival analysis is also biased by censored
patients, i.e., those subjects who are missed at follow-up for
any reason and exit the population “at risk,” thus flattening the
end of the survival curve. If the number of censored subjects
is high, and this might well be the case in long-lasting ALS
trials, it will affect the accuracy of survival estimation. Moreover,
the above requirements are not satisfied by pilot studies, which
usually aim to explore the possibility of a further investment on
a new treatment strategy and therefore switch to functional or
physiological outcome measures.
Traditionally, survival and function have been assessed as
independent endpoints in ALS trials. Combined approaches have
been implemented to reduce the confounding effect of mortality
on analysis of functional outcomes. Most notably, the Combined
Assessment of Function and Survival (CAFS) calculates a rank for
each subject, based on survival time and decline in the ALSFRS-
R score: in this way, a mean rank score can be calculated that
allows for statistical comparison between treatment groups (146).
Additional analytical strategies, such as joint models, have been
implemented to overcome the limitation of CAFS in detecting
functional effects when the rate of mortality is high (147).
Neurophysiological Measures
Neurophysiological techniques might provide an objective
measure of UMN and LMN dysfunction in ALS. For this
reason, they seem to be more sensitive to detect disease
progression with respect to clinical scales. Neurophysiological
abnormalities might also uncover UMN and LMN deficit that
are clinically silent, thus enabling an earlier diagnosis and
thereby recruitment into therapeutic trials. Additionally, they
could provide important insights into disease mechanisms that
ultimately lead to uncovering of novel therapeutic targets.
Biomarkers of UMN Dysfunction
Single and paired-pulse TMS techniques, providing parameters
such as MT, central motor conduction time (CMCT), cortical
silent period, and intracortical inhibition and facilitation,
have gained credibility as a clinical tool to investigate the
integrity and excitability of the corticomotoneuronal system (see
Neurophysiological Insights section above).
Reduced SICI, above all, was reported to be an independent
prognostic biomarker in ALS patients within the first 2 years of
disease onset (148), and in a separate study, SICI was shown to be
partially normalized with riluzole treatment (149). Paralleling the
clinical efficacy of riluzole, the modulating effects lasted about 2
months (150).
Regardless of the underlying mechanisms, studies of
riluzole have suggested a utility of TMS in assessing
biological effectiveness of compounds at an early stage of
drug development. These results suggest that non-invasive in
vivo monitoring of cortical function, and particularly SICI, may
also be an effective biomarker used to monitor the effects of
novel therapeutics in a clinical trial setting.
A limitation of the conventional paired-pulse technique has
been the marked variability in MEP amplitudes with consecutive
stimuli. One of the solutions against this variability problem is
the threshold tracking method, which was developed for paired-
pulse TMS studies and suggested to be a good biomarker in
the assessment of UMN dysfunction in ALS (17, 151). Another
method to overcome this difficulty is the triple stimulation
technique (TST) that provides a measure for conduction
failure (152).
As discussed in a section above, it is still not defined
how TMS metrics change over time. Thus, future studies are
needed to explore the reasons of heterogeneity in cortical
excitability changes during ALS progression and to identify
possible clinical phenotypes and disease trajectories associated to
cortical inexcitability or hyperexcitability.
Even if promising, TMS techniques have some limitations
for disease monitoring (Table 2). Current neurophysiological
methods do not explore function in most of the ancillary
UMN pathways (i.e., tectospinal, rubrospinal, vestibulospinal,
and reticulospinal tracts, as well as various short internuncials
and cerebellar connections), which have a critical role in the
disease process. In addition, the role of UMNpathways within the
spinal cord, an integral component of the central nervous system,
is not well-defined.
Biomarkers of LMN Dysfunction
Conventional neurophysiological techniques, such as nerve
conduction studies which measure the compound muscle
action potential (CMAP) amplitude, may be relatively
insensitive in assessing LMN degeneration due to the process of
reinnervation (153).
The neurophysiological index (NI), using a simple formula,
combines routine CMAP amplitude, F-wave frequency, and
distal motor latency to improve sensitivity in demonstrating
longitudinal LMN loss in ALS (154). NI is also able to
detect LMN loss in muscles of the pre-symptomatic limb as
well as successfully tracking disease progression, demonstrating
continued loss of functional motor units during this pre-
symptomatic period, when weakness, atrophy, or fasciculation
are not detectable to both patients and clinicians (155). The
validation of NI was also demonstrated longitudinally in the
symptomatic muscles and correlated with ALSFRS-R decline
(156, 157). Additionally, NI is able to detect deterioration that
occurred over a short period of 4 weeks in ALS patients, hence
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enabling the utility of this index to monitor treatment efficacy
(158). Therefore, NI is sensitive to LMN loss and weakness in
ALS, whether the disease is rapidly or slowly progressive.
Regarding the use of F-waves, cortical and peripheral
mechanisms have been proposed to account for the F-wave
abnormalities (159, 160). F-wave frequency together with H-
reflex amplitudes and recovery curves are considered as an
indirect measure of spasticity (159), but they correlate poorly
with clinical deficit (161, 162).
Motor unit number estimations techniques, such as
motor unit number estimation (MUNE) and motor unit
number index (MUNIX), may potentially represent valuable
biomarkers of LMN degeneration. Studies utilizing various
MUNE techniques in ALS patients and healthy controls
have reported good intra-rater and inter-rater reliability
(163–165). In addition, progressive linear decline in MUNE
counts has been reported in ALS (166), suggesting utility as
a potential biomarker of disease progression in a clinical trial
setting (164). The MUNIX technique is a method designed
to express the number of functioning motor units within a
muscle as an index, instead of providing a direct measure
of their absolute numbers. Recent studies using different
MUNE methods have demonstrated potential utility for
assessing disease progression in ALS patients as reflected by
a progressive linear decline in MUNE counts (164, 166–169).
Interestingly, a recently developed MUNE technique, termed
MScan, appeared to be the most sensitive MUNE method
in detecting ALS disease progression (169). Additionally,
MUNIX was able to detect disease progression in pre-
symptomatic muscles in ALS (170, 171), and longitudinal
changes in these muscle groups appeared more sensitive than
ALSFRS-R (168).
Peripheral axonal excitability testing provides information
about nodal and internodal axonal ion channel function.
Importantly, the changes in axonal excitability have been
linked to development of muscle cramps, fasciculation, and
motor neuron degeneration (172–174) and have been associated
with a shorter survival (175, 176). Of relevance, a cross-
sectional and a subsequent longitudinal study demonstrated
the effect of riluzole in inducing a significant reduction of
both axonal refractoriness and superexcitability (17), and these
peripheral modulating effects lasted at least 2 months (150). In
addition, excitability measures have also been utilized in clinical
trials assessing the effects of Na+ channel-blocking agents.
Specifically, low-dose mexiletine (300mg) did not exert any
modulating effects on axonal excitability parameters, potentially
accounting for the absence of clinical effectiveness (177).
Separately, axonal excitability studies disclosed stabilization of
axonal ion channel function in patients with ALS treated with
the Na+ channel-blocking agent flecainide (178), associated
with a reduced rate of LMN dysfunction. These clinical
studies underscore the potential of utilizing axonal excitability
parameters as biomarkers of therapeutic effectiveness in a
drug trial setting. Of note, a recent phase 2 trial assessing
efficacy of retigabine, a potassium channel activator, used
successfully axonal excitability parameters as secondary outcome
measures (179).
DISCUSSION AND PERSPECTIVE
Findings of studies on the clinical effects of NIBS in ALS patients
suggest a possible efficacy in determining a slight reduction of
disease progression, related to the duration and frequency of
treatment. However, results were quite variable and of limited
clinical significance. Previous systematic reviews on rTMS for the
treatment of ALS resulted in insufficient evidence on the efficacy
of this type of intervention (180, 181). Latest studies with rTMS
and new methods of stimulation did not add data that could
substantially modify the picture represented by previous analyses
in terms of clinical efficacy; thus, the current evidence must be
considered as preliminary.
Several reasons related to experimental design can account
for the lack of clinically consistent effects. One main limitation
was the lack of a sufficient power to detect small size effects
on selected outcome measures, which did not allow to obtain
informative results in the case of both positive and negative
outcomes. Indeed, all studies in ALS until now, while attempting
to test therapeutic efficacy, recruited no more than 20 subjects in
the active treatment group and did not provide any information
on dose–response relationship, in terms of both tolerability and
efficacy, and therefore do not go beyond the stage of phase 1 trials
(safety evaluation). Moreover, an intrinsic limitation in this field
relates to the fact that most rTMS studies were conducted by the
same research group.
Related to the previous point, it is a matter of great
importance and complexity selecting suitable endpoints, to which
we have dedicated a section of the present work. Indeed,
distinct outcome measures have a different sensitivity in catching
specific functional and pathophysiological alterations that can
be differentially affected during the disease course. Trials with
prolonged (several weeks or months) interventions substantially
used functional and strength scores as the main outcome
measures, with the ALSFRS-R almost constantly employed.
These outcome measures are subject to high variability among
individuals and along disease progression. The existence of
even infrequent “plateaux” and “reversals” in the ALSFRS score
decline (182) further highlights the importance of an appropriate
sample size and limits the reliability of conclusions drawn from
individual case reports. It is quite natural to reason that, in a
disease characterized by rapid progression to death, an effective
treatment should increase the survival rate (or the time interval
to respiratory failure). However, none of the reviewed studies has
a long enough time of observation and a large enough cohort to
allow for a sufficient power in evaluating survival. In fact, survival
was considered as a main efficacy outcome only in reports of
individual cases deviating from the usual disease course [e.g., (91,
99)]. Nonetheless, in possibly subtherapeutic and/or undersized
trials, functional and neurophysiological endpoints remain useful
for preliminarily evaluating the potential biological effects of
a given treatment protocol and for obtaining information on
the feasibility of larger studies. In this context, using objective
neurophysiological markers of UMN and LMN dysfunction
could help to detect the biological effects of interventions targeted
to specific pathophysiological mechanisms in a preliminary
phase; before that, frequency of administration and dosage are
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eventually optimized to obtain therapeutic effects, while it has
been questioned that measures of central motor function can be
useful for monitoring patients in a clinical trial setting (26). It
should also be considered that neurophysiological monitoring
increases the load of experimental procedures and limits the
number of patients who can be recruited.
A second important limitation in ALS trials is the
heterogeneity of recruited patients. Inclusion of subjects
with different phenotypes and/or disease stages considerably
increases the within-group variability and required sample
size. Recruitment difficulties, mainly related to the high effort
required for patients to regularly reach clinical centers to
undergo NIBS procedures and the difficulty to plan the exclusion
of many potentially highly motivated subjects in the absence
of other therapeutic options, could account for study protocols
with wider inclusion criteria.
The disease severity and duration at the time of enrolment
also plays an important role in the evaluation of treatment
outcome, for two main reasons. First, ALS progression,
as evaluated by the ALSFRS score, typically slows in the
more advanced stages (183) and this can mask treatment
effects. Second, based on the hypothesis that hyperexcitability
primes neurodegeneration, experimental treatments aimed at
counteracting hyperexcitability might not be effective in an
advanced stage or in rapidly progressive disease forms,
where neuropathological alterations leading to degeneration
have already occurred. It should also be considered that
cortical and spinal structural changes that might accompany
advanced degeneration could alter the effects of the applied
electric field; however, a clear cortical atrophy is demonstrated
only in ALS subjects with a frontotemporal degeneration
phenotype (184, 185).
Dealing with the purpose of early recruitment is challenging
since the sensitivity of the clinically based criteria is limited,
particularly in the early stages of ALS (186–188), leading to
significant diagnostic delays and thereby a delay in institution of
neuroprotective therapies and recruitment into therapeutic trials
(189). To this end, neurophysiological techniques might be more
sensitive in detecting UMN and LMN deficits that are clinically
silent, thus enabling an earlier diagnosis and disease-modifying
interventions. For example, it was suggested that biomarkers that
can detect changes in the integrity of the corticomotoneuronal
synapse should be able to identify the earliest stages of ALS (190).
Besides limitations related to experimental design, the
characteristics and neurobiological effects of brain stimulation
interventions must be considered. We described how different
NIBS protocols interact with corticospinal circuitry. Protocols
targeting indirect intracortical connections with CSNs (i.e.,
those affecting later I waves), such as 1-Hz rTMS, PAS, and
cathodal tDCS, have the potential to interact with mechanisms of
hyperexcitability related to hypoactive GABAergic interneurons,
demonstrated by neurophysiological and neuropathological
investigations. Otherwise, protocols targeting direct projections
to CSNs or CSNs themselves, such as cTBS and possibly tDCS,
could reduce intrinsic UMN excitability. However, based on
current knowledge, it is not possible to foresee which of the above
hypothetical mechanisms (upstream or direct interaction with
CSNs) will be more efficient. This is substantially due to a still
insufficient knowledge on the pathological cascade at single-cell
level and on the exact interaction of brain stimulation techniques
with individual cell populations. Moreover, we do not know
to which extent counteracting corticospinal hyperactivity might
prevent LMN degeneration (191), even if this approach has a
strong rationale in the theory of cortical-driven excitotoxicity.
Studies on ALS patients also do not provide sufficient
indications on what might be the best stimulation paradigm.
To date, cTBS was tested in the majority of patients, with some
favorable results in the first months of treatment (88) and at
higher dosage (93). The 1-Hz rTMS showed promising results
but it was tested only in a very preliminary study (87). Cathodal
tDCS seems to be ineffective in preliminary observations (94, 96,
105), while a recent wider study suggests a functional effect of
corticospinal tDCS (95) but limited by the fact that stimulation
was applied only for 2 weeks (Table 1). Of note, with tDCS,
individualized electric field modeling (192, 193) could improve
stimulation targeting and dosing of current density in target
brain areas.
Experimental data also suggest that hyperexcitability in ALS
might be a compensatory phenomenon of cell loss (191): in
this case, inhibitory brain stimulation protocols would not
be effective in slowing progression of pathogenic processes.
However, facilitatory rTMS protocols, which might ease this
compensatory phenomenon, seem ineffective, even if tested in
very preliminary studies (Table 1).
Finally, it must be accepted that, if most or the totality of
ALS forms depend on gene alterations and if hyperexcitability
is not a causal factor of neuropathological alterations and cell
loss, all interventions targeted to counteracting hyperexcitability
can be expected, at best, to slow the disease progression without
substantial effects on long-term survival.
In any case, since the physiological effect of NIBS techniques
on cortical excitability is usually short-lasting, the time
during which the motor cortex is exposed to stimulation
appears as a key factor to produce clinically significant
effects. The application of rTMS protocols is limited by the
necessity of being administered within the hospital, while
tDCS could be implemented for home self-administration. The
administration at the patient’s site of a new NIBS technique,
transcranial static magnetic field stimulation (194, 195), has
been recently proposed in ALS (196) and is currently being
tested in a randomized controlled trial (ClinicalTrials.gov
ID: NCT04393467). Alternatively, implanted devices could
warrant prolonged daily stimulation, but their interaction with
intracortical circuits is still largely unexplored.
In conclusion, in our view, there are few approaches that could
warrant informative results from future trials.
• Targeted patients’ selection. Subjects in the early stages
of disease, stratified based on clinical characteristics and
biomarkers, could represent a population exhibiting less
variability and more likely to benefit of the potential disease-
modifying effect of brain stimulation interventions.
• Adequate sample size. Samples larger than those tested until
now, which could be obtained with multicenter studies, will
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allow to perform phase 2 or phase 3 clinical trials once a
promising intervention has been defined from pilot studies.
• Targeted stimulation protocols with appropriate outcome
measures. Further research on the mechanisms of
corticospinal dysfunction in ALS and on the way to target
specific cortical or corticospinal circuits will allow to target
specific pathophysiological mechanisms. Neurophysiological
or molecular biomarkers could allow to detect biological
effects of proposed treatments before their clinical translation.
• Ensuring suitable stimulation dosage. Based on the current
knowledge on the time course of neurophysiological effects of
most brain stimulation techniques, it appears that protocols
tested until now are likely underdosed to produce clinically
significant effects. Increased dosage can be ensured with
either repeated sessions of self-administered non-invasive
stimulation or continuous stimulation delivered through
implanted devices. The best risk-to-benefit ratio for different
protocols remains to be determined.
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